2023
Abstract LB237: Functional characterisation of TRACERx reveals mechanisms of NSCLC evolution
Lu W, Zalmas L, Bailey C, Pich O, Ruiz C, Black J, Stavrou G, Biswas D, Gimeno-Valiente F, Litchfield K, Bartek J, McGranahan N, Kanu N, Swanton C. Abstract LB237: Functional characterisation of TRACERx reveals mechanisms of NSCLC evolution. Cancer Research 2023, 83: lb237-lb237. DOI: 10.1158/1538-7445.am2023-lb237.Peer-Reviewed Original ResearchNon-small cell lung cancerElevated chromosomal instabilityWhole-genome doublingChromosomal instabilityIntratumoral heterogeneityHomologous recombination repairDNA damage responseAmerican Association for Cancer Research annual meetingsPC9 cellsRates of acquired resistanceIncreased intratumoral heterogeneityCell lung cancerIncreased CINDrug-resistant tumorsGenome doublingFunctional characterisationStructural chromosome instabilityWhole-genome doubling eventsFAT1 mutationsHomologous recombination repair pathwayBRCA1 foci formationChromosomal gainsMitotic error rateTargeted therapySolid tumors
2022
Abstract 645: Heterogeneity of immunotherapy biomarkers in the TRACERx non-small cell lung cancer multi-region lung cancer cohort study
Hiley C, Litchfield K, Pich O, Moore D, Naceur-Lombardelli C, Veeriah S, Bakir M, Summan S, Grigoriadis K, Ruiz C, Puttick C, Enfield K, Ward S, Frankell A, Biswas D, Rosenthal R, Birkbak N, Jamal-Hanjani M, McGranahan N, Swanton C, Consortium T. Abstract 645: Heterogeneity of immunotherapy biomarkers in the TRACERx non-small cell lung cancer multi-region lung cancer cohort study. Cancer Research 2022, 82: 645-645. DOI: 10.1158/1538-7445.am2022-645.Peer-Reviewed Original ResearchNon-small cell lung cancerTumor mutational burdenIntra-tumor heterogeneityIntratumoral heterogeneityCancer Cohort StudyImmunotherapy biomarkersTumor regionAmerican Association for Cancer Research annual meetingsPredictors of response to immunotherapyCohort studyPrediction of immunotherapy responseTumor purityNeo-adjuvant settingResponse to immunotherapyFirst-line therapyImpact of intratumoral heterogeneityCell lung cancerMisclassification of patientsWhole-exome sequencingHeterogeneity of expressionMetastatic settingPDL1 immunohistochemistryPrimary tumorImmunotherapy responseMutational burden